What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹1,735 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from HIKAL LIMITED's filed financials and exchange disclosures
HIKAL LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol HIKAL.
No. Over the trailing twelve months HIKAL LIMITED reported a net loss of ₹34 Cr on revenue of ₹1,735 Cr.
Yes. The dividend yield is 0.44% at the current price.
No. Debt stands at 0.57× equity, and it carries net debt of ₹672 Cr. That is lower than 15% of its 171 Pharmaceuticals peers.
On a typical session HIKAL LIMITED moves 1.41% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by HIKAL LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
